Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete Response



Status:Recruiting
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:9/22/2018
Start Date:July 12, 2016
End Date:April 18, 2022

Use our guide to learn which trials are right for you!

Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete Responders

This randomized phase II trial studies how well obinutuzumab works as maintenance treatment
in patients with central nervous system lymphoma who have achieved the disappearance of all
signs of cancer in response to treatment (complete response). Monoclonal antibodies, such as
obinutuzumab, may kill cancer cells that are left after chemotherapy.

PRIMARY OBJECTIVES:

I. To determine the effect of maintenance obinutuzumab on duration of complete response (CR)
in patients with CD20+ B-cell primary central nervous system lymphoma (PCNSL) who attain CR
to first-line treatment with high-dose methotrexate-based chemotherapy.

SECONDARY OBJECTIVES:

I. To evaluate overall survival after CR (overall survival [OS]-CR). II. To evaluate
neurocognitive function, quality of life, and neuroimaging as indicators of neurotoxicity.

III. Progression-free survival (PFS) and overall survival will be calculated.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I (MAINTENANCE THERAPY): Patients receive obinutuzumab intravenously (IV) on days 1 and 2
for the first course, and on day 1 for the subsequent courses. Courses repeat every 60 days
for 2 years in the absence of disease progression or unacceptable toxicity.

ARM II (OBSERVATION): Patients undergo observation for a total of 3 years.

After completion of study treatment, patients are followed up every 3 months for 1 year.

Inclusion Criteria:

- CD20+ B-cell primary central nervous system lymphoma (PCNSL) confirmed at the time of
diagnosis by histology, cytology, or immunocytochemistry from cerebrospinal fluid
(CSF); diagnosis must be documented by pathology report

- Must have undergone first-line treatment with a high-dose methotrexate-based
chemotherapy regimen with or without brain radiotherapy; high-dose methotrexate is
defined as >= 3 grams/m^2; methotrexate dose reduction for creatinine clearance < 100
ml/min is permitted

- Must be within 75 days of completion of first-line treatment regimen; must have
achieved complete response (CR/unconfirmed complete response [CRu]) to first-line
treatment

- Brain magnetic resonance imaging (MRI) documenting CR must be obtained within 30 days
of study enrollment

- If CSF was positive for lymphoma cells at diagnosis or during first-line treatment
and/or a slit lamp examination was positive at diagnosis or during first-line
treatment, then the CSF and vitreal studies must have been repeated and must have
indicated CR; Note: CR requires complete disappearance of all enhancing abnormalities
on gadolinium-enhanced MRI; if CSF was positive for lymphoma cells at diagnosis or
during first-line treatment and/or slit lamp examination was positive at diagnosis or
during first-line treatment, then the CSF and vitreal studies must have been repeated
and must have indicated CR; for CRu, some patients will have a small but persistent
enhancing abnormality on MRI related to biopsy or focal hemorrhage; it is often
difficult to ascertain whether this represents a residual nidus of tumor or scar
tissue; if the abnormality does not change or slowly involutes without therapy and
corticosteroids, it is reasonable to categorize as a CRu; at the time CR/CRu is
determined, the patient should not have used corticosteroids for at least two weeks

- Karnofsky performance status (KPS) >= 60; Eastern Cooperative Oncology Group (ECOG) 0,
1, or 2

- Signed informed consent form (ICF)

- Ability and willingness to comply with the requirements of the study protocol

- Total bilirubin < 3 x the upper limit of normal (ULN), +/- 7 days from date of ICF
signing

- Creatinine clearance > 30 mL/min (calculated according to institutional standards or
using Cockcroft?Gault formula), +/- 7 days from date of ICF signing

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 5 x ULN, +/- 7
days from date of ICF signing

- Platelet >= 75,000 cells/mm^3, +/- 7 days from date of ICF signing

- Hemoglobin > 9 g/dL, +/- 7 days from date of ICF signing

- Absolute neutrophil count > 1.5 x 10^3 cells/mm^3, +/- 7 days from date of ICF signing

- Surgically sterile or agree to use effective contraception using an adequate measure
of contraception such as oral contraceptives, intrauterine device, or barrier method
of contraception in conjunction with spermicidal jelly while receiving obinutuzumab
and >= 12 months after the last dose of obinutuzumab for women, and 3 months after the
last dose of obinutuzumab for men

Exclusion Criteria:

- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy

- Clinical evidence of extra-central nervous system (CNS) (systemic) non-Hodgkin
lymphoma

- Known hypersensitivity to any of the study drugs

- History of other malignancy that could affect compliance with the protocol or
interpretation of results

- Patients with a history of curatively treated basal or squamous cell carcinoma of
the skin or in situ carcinoma of the cervix are generally eligible; patients with
a malignancy that has been treated, but not with curative intent, will also be
excluded, unless the malignancy has been in remission without treatment for >= 2
years prior to enrollment

- Known active bacterial, viral, fungal, mycobacterial, or other infection (excluding
fungal infections of nail beds) or any major episode of infection requiring treatment
with IV antibiotics or hospitalization (related to the completion of the course of
antibiotics) within 4 weeks prior to study enrollment

- Major surgery within 4 weeks prior to study enrollment

- Known infection with human immunodeficiency virus (HIV)

- Known positive hepatitis serologies:

- Hepatitis B (HBV): patients with positive serology for hepatitis B defined as
positivity for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody
(anti-HBc); patients who are positive for anti-HBc may be considered for
inclusion in the study on a case-by-case basis if they are hepatitis B viral
deoxyribonucleic acid (DNA) negative and are willing to undergo ongoing HBV DNA
testing by real-time polymerase chain reaction (PCR); patients with positive
serology may be referred to a hepatologist or gastroenterologist for appropriate
monitoring and management

- Hepatitis C (HCV): patients with positive hepatitis C serology unless HCV
ribonucleic acid (RNA) is confirmed negative and may be considered for inclusion
in the study on a case-by-case basis

- Women who are pregnant or lactating

- Fertile men or women of childbearing potential unless 1) surgically sterile or 2)
using an adequate measure of contraception such as oral contraceptives, intrauterine
device, or barrier method of contraception in conjunction with spermicidal jelly

- Effective contraception is required while receiving obinutuzumab; for women, effective
contraception is required to continue for >= 12 months after the last dose of
obinutuzumab; for men, effective contraception is required to continue for 3 months
after the last dose of obinutuzumab treatment

- Vaccination with a live vaccine a minimum of 4 weeks prior to study enrollment
We found this trial at
9
sites
3181 S.W. Sam Jackson Park Road
Portland, Oregon 97239
503 494-7999
Principal Investigator: Edward A. Neuwelt
Phone: 503-494-5626
OHSU Knight Cancer Institute OHSU Knight Cancer Institute is known worldwide for our contributions to...
?
mi
from
Portland, OR
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Larry R. Junck
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Charlottesville, Virginia 22903
(434) 924-0311
Principal Investigator: David Schiff, MD
Phone: 434-924-5610
University of Virginia The University of Virginia is distinctive among institutions of higher education. Founded...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
18101 Lorain Avenue
Cleveland, Ohio 44111
216.476.7000
Principal Investigator: David M. Peereboom
Phone: 216-445-6068
Cleveland Clinic Cancer Center at Fairview Hospital Fairview Hospital is a 488-bed hospital located at...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Edward Pan, MD
Phone: 214-645-4673
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denver, Colorado 80210
Principal Investigator: Douglas E. Ney
Phone: 720-848-0650
?
mi
from
Denver, CO
Click here to add this to my saved trials
500 University Dr
Hershey, Pennsylvania 17033
(717) 531-6955
Principal Investigator: Michael Glantz, MD
Phone: 717-531-0003
Penn State Milton S. Hershey Medical Center Penn State Milton S. Hershey Medical Center, Penn...
?
mi
from
Hershey, PA
Click here to add this to my saved trials
Providence, Rhode Island 02903
Principal Investigator: Alexander Mohler
Phone: 401-444-3234
?
mi
from
Providence, RI
Click here to add this to my saved trials
Medical Center Boulevard
Winston-Salem, North Carolina 27157
336-716-2255
Principal Investigator: Roy E. Strowd
Phone: 336-713-5440
Comprehensive Cancer Center of Wake Forest University Our newly expanded Comprehensive Cancer Center is the...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials